Nature Communications (Jan 2023)
Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer
- Song Li,
- Wenbin Yu,
- Fei Xie,
- Haitao Luo,
- Zhimin Liu,
- Weiwei Lv,
- Duanbo Shi,
- Dexin Yu,
- Peng Gao,
- Cheng Chen,
- Meng Wei,
- Wenhao Zhou,
- Jiaqian Wang,
- Zhikun Zhao,
- Xin Dai,
- Qian Xu,
- Xue Zhang,
- Miao Huang,
- Kai Huang,
- Jian Wang,
- Jisheng Li,
- Lei Sheng,
- Lian Liu
Affiliations
- Song Li
- Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University
- Wenbin Yu
- Department of General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University
- Fei Xie
- Department of Pharmacy, Qilu Hospital, Cheeloo College of Medicine, Shandong University
- Haitao Luo
- Shenzhen Yucebio Technology Co., Ltd., Shenzhen
- Zhimin Liu
- Department of General Surgery, Zibo Municipal Central Hospital, Binzhou Medical College
- Weiwei Lv
- Department of Radiology, Qilu Hospital, Cheeloo College of Medicine, Shandong University
- Duanbo Shi
- Department of Pathology, Qilu Hospital, Cheeloo College of Medicine, Shandong University
- Dexin Yu
- Department of Radiology, Qilu Hospital, Cheeloo College of Medicine, Shandong University
- Peng Gao
- Department of Pathology, Qilu Hospital, Cheeloo College of Medicine, Shandong University
- Cheng Chen
- Department of General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University
- Meng Wei
- Department of General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University
- Wenhao Zhou
- Shenzhen Yucebio Technology Co., Ltd., Shenzhen
- Jiaqian Wang
- Shenzhen Yucebio Technology Co., Ltd., Shenzhen
- Zhikun Zhao
- Shenzhen Yucebio Technology Co., Ltd., Shenzhen
- Xin Dai
- Department of Medical Oncology, Shandong Provincial Hospital of Traditional Chinese Medicine
- Qian Xu
- Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University
- Xue Zhang
- Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University
- Miao Huang
- Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University
- Kai Huang
- Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University
- Jian Wang
- Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University
- Jisheng Li
- Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University
- Lei Sheng
- Department of General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University
- Lian Liu
- Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University
- DOI
- https://doi.org/10.1038/s41467-022-35431-x
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 16
Abstract
Immune checkpoint inhibitors and antiangiogenic agents have shown some activity in patients with late-stage gastric cancer. Here the authors report the results of a phase II trial of neoadjuvant anti-PD1 (camrelizumab), antiangiogenic agent (apatinib), and chemotherapy (S-1 ± Oxaliplatin) in stage T4a/bN + M0 gastric cancer patients.
